NEUROONE MEDICAL TECHNOLOGIES Corp Liquidation Value

NMTC Medical Devices

Cash & Equivalents

$2.80M
As of 2026-03-31
Current Price: N/A

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $2.80M
Total Obligations: -$1.99M
$815,223
Per share: $0.09
Period: 2026-03-31
incomplete 1 component missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $2.80M
AR: $2.43M
Total Obligations: -$1.99M
$3.24M
Per share: $0.38
Period: 2026-03-31
incomplete 1 component missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $2.80M
AR: $2.43M
Inventory: $1.87M
Total Obligations: -$1.99M
$5.11M
Per share: $0.59
Period: 2026-03-31
incomplete 1 component missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$815,223$0.09
Liquid Liquidation Value$3.24M$0.38
Operating Liquidation Value$5.11M$0.59

Key Components (as of 2026-03-31)

Data as of 2026-03-31 from 10-Q filed 2026-05-12. View on SEC EDGAR →

Cash & Equivalents$2.80M
Accounts Receivable$2.43M
Inventory$1.87M
Current Liabilities$1.69M
Long-term Debt (?)N/A
Op. Lease Liability (?)$92,361
Finance Lease (?)N/A
Shares Outstanding8.6M

Explore all 101 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2026-03-31$2.80M$2.43M$1.87M$934,196$1.69MN/A$92,361N/A
2025-12-31$3.56M$2.66M$1.67M$552,332$1.26MN/A$110,374N/A
2025-09-30$6.57M$1.26M$2.23M$1.01M$2.30MN/A$143,148N/A
2025-06-30$8.04MN/A$1.90M$467,734$1.43MN/A$175,344N/A
2025-03-31$1.32M$318,780$1.83M$910,754$1.76MN/A$206,973N/A
2024-12-31$1.13M$2.37M$1.93M$744,525$1.57MN/A$237,377N/A
2024-09-30$1.46M$176,636$2.64M$1.03M$2.21M$5.00M$194,392N/A
2024-06-30$1.62M$410,551$1.79M$759,260$1.69MN/A$209,910N/A

Comments

SEC Filings

PeriodFormFiledLink
2026-03-31 10-Q 2026-05-12 View
2025-12-31 10-Q 2026-02-17 View
2025-09-30 10-K/A 2026-01-23 View
2025-09-30 10-K 2025-12-17 View
2025-06-30 10-Q 2025-08-14 View
2025-03-31 10-Q 2025-05-13 View
2024-12-31 10-Q 2025-02-12 View
2024-09-30 10-K 2024-12-17 View

AI Insights

AI Insight·Generated 2026-05-13

NMTC presents a deeply negative liquidation posture as of March 31, 2026. Applying standard liquidation haircuts to the XBRL-tagged asset base: cash of $2.8M recovers at 100% ($2.8M); accounts receivable of $2.4M at 90-95% ($2.2-2.3M); inventory of $1.9M at 60% ($1.1M); PP&E net of $231K at 50-70% ($115-162K); intangibles of $34K at 0%; operating lease ROU asset at 0%; deferred offering costs at 0%. Total estimated liquidation recovery on assets is approximately $6.2-6.4M. Against this, total liabilities of $2.5M settle at face value, comprising current liabilities of $1.7M (accounts payable $934K, accrued liabilities $755K, current lease obligations $115K) and non-current liabilities of $802K (warrant liability at fair value $710K, non-current lease $92K). Estimated net recovery to equity under liquidation is approximately $3.7-3.9M, which compares to the MFFAIS-reported OLV of $5.1M. The principal recovery driver is cash ($2.8M), with AR ($2.4M gross, heavily concentrated—one customer represents 99.7% of H1 product revenue, per MD&A) providing the second-largest asset. The warrant liability ($709K, Level 3 fair value via Monte Carlo simulation) sits at face value on the liability side and is not extinguished at zero in a wind-up scenario. The accumulated deficit reached $82.1M. Cash burned $4.4M from operations in H1 FY2026, down from $2.8M in cash at period end versus $3.6M at the prior quarter end (December 31, 2025). Management disclosed substantial doubt about going concern. The company executed a March 2026 private placement ($670K gross, 166,666 shares to a newly appointed officer) and received $174K from warrant exercises during the six-month period, partially offsetting operational cash consumption. A 6-for-1 reverse stock split was effected post-period (April 15, 2026); all share figures in the filing are retroactively adjusted. The accounts receivable balance more than doubled relative to the prior quarter—a $1.2M increase per the cash flow statement—reflecting revenue ramp without cash collection, compressing near-term liquidity. No debt drawn; the terminated Debt Facility ($3M capacity) generated no principal balance but resulted in $125K termination fee plus related costs previously expensed. License revenue ($3.0M Zimmer milestone recognized in Q1 FY2025) is non-recurring and absent from the current period, explaining the sharply worse six-month operating loss ($3.8M vs. $969K in H1 FY2025). Filing discusses royalty obligations under WARF and Mayo agreements in MD&A but does not separately tag the contingent future royalty commitment quantum in XBRL. Material weakness in segregation of duties remains unremediated.

Flags

Loading flags...

AI Insight Discussion

Loading...

Community Notes

Loading notes...

Questions

Loading questions...